# FDA Requires GLP-1 Makers to Warn of Vision Loss Risk

> FDA orders GLP-1 drug makers to alert patients about potential vision loss side effects.
- Title: FDA Requires GLP-1 Makers to Warn of Vision Loss Risk
- Summary: FDA orders GLP-1 drug makers to alert patients about potential vision loss side effects.
- Keywords: fda, glp-1, vision loss, ozempic, wegovy, naion, eye stroke, The Washington Post
- Source: The Washington Post — https://washingtonpost.com/health/2026/11/09/fda-tells-glp-1-makers-warn-potential-vision-loss-side-effect
- Read time: 1 min
- Topics: fda, glp-1, vision loss, ozempic, wegovy, naion, eye stroke, business, finance
## FDA mandates GLP-1 warning
The Food and Drug Administration requires manufacturers of GLP-1 medications to warn patients about increased risk of vision loss.
## GLP-1 drugs linked to eye stroke
GLP-1 medications can cause non-arteritic anterior ischemic optic neuropathy, a rare condition where vision loss occurs due to lack of blood flow to the optic nerve.
## NAION risk is very low
Experts say the absolute risk of NAION is extremely low, affecting about six in 100,000 patients.
## FDA reviews studies and lawsuits
The FDA cited a 2024 study of 16,000 patients and numerous lawsuits alleging vision loss after GLP-1 use.
## Drug companies respond
Eli Lilly, Novo Nordisk, and Sanofi state they will evaluate the FDA update and emphasize patient safety.
## Patients advised to seek help
Patients should contact doctors immediately if experiencing vision symptoms and discuss continuing or stopping GLP-1 medications.
## Key takeaway

FDA mandates GLP-1 manufacturers to warn of increased vision loss risk from drugs like Ozempic and Wegovy.